January 1997

Smoking Affects Plasma-Soluble Interleukin-2 Receptor Levels in Patients With Schizophrenia

Author Affiliations

Max Planck Institute of Psychiatry Clinical Institute Kraepelinstrasse 10 Munich D-80804 Germany

Arch Gen Psychiatry. 1997;54(1):89. doi:10.1001/archpsyc.1997.01830130095017

Ganguli and colleagues,1 in the August 1995 issue of the ARCHIVES, provide convincing evidence that phytohemagglutinin-induced in vitro interleukin-2 (IL-2) production is reduced in patients with schizophrenia who have never received medication compared with healthy control subjects. They note that decreased IL-2 secretion and increased systemic levels of soluble IL-2 receptors (sIL-2Rs) are robust findings that signify an alteration of immunologic functions in patients with schizophrenia. Documentation of altered IL-2 secretion in drug-naive patients is important because antipsychotic medication can influence the IL-2/IL-2 receptor system as demonstrated by clozapine-induced increases in plasma sIL-2R levels.2

In addition to antipsychotic medication, smoking may affect the immune system of patients with schizophrenia. In healthy smokers, phytohemagglutinininduced lymphocyte proliferation was shown to be suppressed,3 and systemic sIL-2R levels were reported to be increased.4,5 The prevalence of smoking is high in patients with schizophrenia,6 but neither the study by Ganguli

First Page Preview View Large
First page PDF preview
First page PDF preview